

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bruce A. Yankner and Philip Nadeau

Serial No.: Divisional of 09/239,387

Art Unit: Not Yet Assigned

Filed: February 28, 2002

Examiner: Not Yet Assigned

For: *METHODS FOR DECREASING BETA AMYLOID PROTEIN*

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including three (3) pages of Form PTO-1449. The documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/239,387, filed January 28, 1999, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.



Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 95/06470 A1	03-09-1995	Merck & Co., Inc.	PCT
WO 97/48701 A1	12-24-1997	Pfizer, Inc.	PCT
WO 99/38498 A1	08-05-1999	Warner-Lambert Company	PCT
WO 98/47518 A1	10-29-1998	Europaisches Laboratorium for Molekular Biologie	PCT
WO 99/15159 A1	04-01-1999	Nova Molecular, Inc.	PCT

Publications

ALLEN, et al., "A noninstrumented quantitative test system and its application for determining cholesterol concentration in whole blood," *Clin Chem* 36(9):1591-7 AN-113:207679 CA (1990).

BROWN, et al., "A receptor-mediated pathway for cholesterol homeostasis," *Science* 232(4746):34-47 (1986).

BUSCIGLIO, et al., "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells," *Proc. Nat. Acad. Sci.* 90, 2092-2096 (1993)

FARRER, et al., "Assessment of Genetic Risk for Alzheimer's Disease among First-Degree relatives," *Ann. Neurol.* 25: 485-492 (1989)

FREARS, et al., "The role of cholesterol in the biosynthesis of beta-amyloid," *Neuroreport* 10(8):1699-705 (1999).

GOATE, et al., (1991) "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," *Nature* 349, 704-706).

JARVIK, et al., "Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study," *Neurology* 45(6):1092-96 (1995).

MANN and ESIRI, "The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's Syndrome," *J. Neurol. Sci.* 89, 169-179 (1984).

MCKHAHN, et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease," *Neurology* 34:939-944 (1984)

REIMAN, et al., "Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the $\epsilon 4$ Allele for Apolipoprotein E," *N.E.J.Med.* 334, 752-758 (1996)

SELKOE, D.J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," *Science* 275, 630-631 (1997))

SPARKS, D.L., "Intraneuronal β -Amyloid Immunoreactivity in the CNS," *Neurobiology of Aging*. 17, 291-299 (1996)

SPARKS. et al., "Dietary cholesterol induces Alzheimer-like β -amyloid immunoreactivity," *Nutr., Metab. Cardiovasc Dis.* 7(3):255-266 AN-127:135116 CA (1997).

STRITTMATTER, et al., "Apolipoprotein E: High-avidity binding to β -amyloid and increases frequency of type 4 allele in late-onset familial Alzheimer disease," *Proc. Natl. Acad. Sci. U.S.A.* 90:1977-1981 (1993),

TANIGUCHI, et al., "Method for assaying soluble amyloid precursor protein [APP]," *Eur Pat Appl.* AN-127-106355 CA (1997).

VAN DULJN, et al., "Familial Aggregation of Alzheimer's Disease and Related Disorder's: A Collaborative Re-Analysis of Case-Control Studies," *Int. J. Epidemiol.* 20 (suppl 2), S13-S20 (1991)


WISNIEWSKI, et al., "Is Alzheimer's disease an apolipoprotein E amyloidosis?" *Lancet* 345(8955):956-8 (1995).

YANKNER, "Mechanisms of Neuronal Degeneration in Alzheimer's Disease," *Neuron* 16:921-932. (1996).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: February 28, 2002

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8500
FAX 404-817-0470
www.hklaw.com

Divisional of U.S.S.N. 09/239,387
Filed: February 28, 2002
INFORMATION DISCLOSURE STATEMENT
Express Mail Label No.: EL 778 571 835 US
Date of Deposit: February 28, 2002

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this paper and any documents referred to as attached or enclosed are being deposited with the United States Postal Service on this date, February 28, 2002, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Express Mail Label No. EL 778 571 835 US, addressed to Box Patent Application, Commissioner of Patents and Trademarks, Washington, D.C. 20231.



Pam Turnbough

Date: February 28, 2002